Please login to the form below

Zontivity

This page shows the latest Zontivity news and features for those working in and with pharma, biotech and healthcare.

FDA reviewer backs approval of TMC's cangrelor

Additional competition in the category will also come from Merck &Co's first-in-class protease-activated receptor-1 (PAR-1) antagonist Zontivity (vorapaxar) - which was cleared for marketing in the

Latest news

R&D productivity takes off

Other first-in-class agents include: Merck &Co's PAR-1 antagonist Zontivity (vorapaxar), a novel antiplatelet agent; AstraZeneca's PARP inhibitor Lynparza (olaparib) for cancer; Otsuka's Deltyba (delamanid), a
Orphan drugs in latest CHMP recommendations

s Zontivity (vorapaxar), which was recommended for the reduction of atherothrombotic events.
Merck's first-in-class Zontivity cleared in US

Merck's first-in-class Zontivity cleared in US. FDA approves the protease-activated receptor-1 antagonist to reduce heart attack risk. ... Merck plans to launch Zontivity in the US in the coming weeks, while the PAR-1 antagonist is also under regulatory
FDA panel backs Merck's vorapaxar

Vorapaxar - which Merck plans to sell under the brand name Zontivity - is an orally-active protease-activated receptor 1 (PAR-1) inhibitor that targets thrombin-induced platelet activation. ... If the FDA follows the panel's advice - which it generally

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Deal Watch September 2016

Merck &Co has sold the US and Canadian rights for its Zontivity, or vorapaxar, to Aralez Pharmaceuticals in an asset purchase agreement worth $25m. ... Zontivity is a protease-activated receptor-1 antagonist indicated for use in combination with daily

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Multi-Channel Account Managers - Road / Homebased – Full or Part...: Competitive salary

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Editorial Director – Medical Education (MedComms): Neg

Client Services Director - Med Comms: Great salary and bebefits

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Home based, Editorial Team Leader, Medical Communications: Excellent package

Senior Project Manager - Medical Writing: Great salary and bebefits

Home based, Chief Medical Writer, Medical Communications: Excellent package

Home based, Senior Medical Writer, Medical Communications: Excellent package

Client Services Director – Healthcare Advertising - London: Neg

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Account Manager: £40, 000 - £45, 000 benefits

Senior Account Manager: Competitive salary commensurate with experience

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Home based, Principal Medical Writer, Medical Communications: Excellent package

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Business Unit Head, Medical Communications, London: Excellent package

Delivery Manager/ Head of Delivery – Executive Search: Neg

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Subscribe to our email news alerts

PMHub

Add my company

Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape: Is it a solution to addressing the challenges of the value-based marketplace?...
Creativity has lost its worth: Creativity has lost its worth, and sadly it is undermining effectiveness...